Organigram Global Inc. · TSX:OGI

Organigram Global — Investor Presentation (March 2021)

11 slides from Organigram Global's investor presentation, Mar 11, 2021

  1. Slide 1: Product Development Collaboration and Strategic Investment

    DRAFT – PRIVATE & CONFIDENTIAL & PRODUCT DEVELOPMENT COLLABORATION AND STRATEGIC INVESTMENT MARCH 11, 2021 OGI INVESTORS’ PRESENTATION |

  2. Slide 2: Cautionary Statement

    Cautionary Statement This document is current as of March 10, 2021, except where otherwise stated. The information contained in Organigram’s profile on SEDAR (see www.sedar.com) and filed or furnished to the Securities and Exchange this presentation is provided by Organigram (“OGI” or the “Company”)

  3. Slide 3: Organigram at a Glance

    ORGANIGRAM AT A GLANCE LEADING LICENSED 3 LEVEL INDOOR PRODUCER FACILITY INTERNATIONAL Leading licensed In Moncton, NB with Serving Israeli INNOVATION CANADIAN producer (LP) of quality micro-climate, strain PROVINCES & Australian medical Focused on products for specific rooms, edibles Sales to all m

  4. Slide 4: Organigram at a Glance

    ORGANIGRAM AT A GLANCE MRQ – Q1 Fiscal 2021 Comprehensive Product and Brand Portfolio • Revitalizing entire product portfolio with signs of success • 42% YoY and 14% sequential growth in adult-use recreational gross revenue, respectively • Positive operating cash flow for the 2nd quarter of the last

  5. Slide 5: OGI Focused on Innovation and R&D

    OGI FOCUSED ON INNOVATION AND R&D PROPRIETARY NANO- BIOSYNTHESIS EMULSIFICATION • OGI’s investment in Hyasynth, a biotech • Proprietary nano-emulsification leader in the field of cannabinoid science technology developed by R&D team makes it one of only two cannabis producers • Launched as RE:MIX dis

  6. Slide 6: Transaction Highlights and Strategic Rationale

    TRANSACTION STRATEGIC RATIONALE HIGHLIGHTS  Accelerates and strengthens Organigram’s R&D and ~C$221M Strategic Investment from Subsidiary of BAT for 19.9% product development activities, including granting Equity Interest in OGI access to certain BAT-owned IP  Raises significant capital to invest

  7. Slide 7: Alignment of Capabilities & Resources

    ALIGNMENT OF CAPABILITIES & RESOURCES LEADING CONSUMER GOODS BUSINESS LEADING LICENSED PRODUCER OF HIGH-QUALITY CANNABIS PRODUCTS SOPHISTICATED MANAGEMENT STATE-OF-THE-ART MONCTON FACILITY INNOVATIVE PRODUCT PLATFORMS EXPERIENCED MANAGEMENT TEAM DEEP PLANT EXPERTISE WITH DEEP CANNABIS EXPERTISE DEEP

  8. Slide 8: Product Development Collaboration

    PRODUCT DEVELOPMENT COLLABORATION Center of Excellence (“CoE”) • Located at OGI’s Moncton facility, which holds the Health Canada licenses required to conduct research and development activities with cannabis products • Focused on developing the next generation of cannabis products with an initial f

  9. Slide 9: Transaction Summary

    TRANSACTION SUMMARY • Subsidiary of BAT subscribed for 58.3M common shares of OGI, which represents a 19.9% equity interest1 on a post-transaction basis, at a price of C$3.792 per share Investment • Total proceeds to OGI of ~C$221 million (the “Investment Proceeds”) • The price per share is based on

  10. Slide 10: Pro Forma Capitalization and Ownership

    PRO FORMA CAPITALIZATION AND OWNERSHIP Organigram BAT Investment Organigram (Pre-Transaction)(1) (Pro Forma) Basic Shares 234.8M 58.3M 293.1M Outstanding(2) Cash and Short- C$75M C$221M C$296M Term Investments 10 1. As of Mar 9, 2021 2. Non-diluted shares outstanding.

  11. Slide 11: Thank You

    DRAFT – PRIVATE & CONFIDENTIAL THANK YOU OGI INVESTORS’ PRESENTATION |

Organigram Global — Investor Presentation (March 2021) on 6ix